Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00477750 · OUTCOME

Overall Survival (OS) at 3 Years

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2019-10-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
registration to death (up to 3 years)

What was measured

OS was defined as the time from registration to death due to any cause. Patients who were alive were censored at date of last follow-up. The overall survival at 3 years (a percentage) is reported below.

Analysis population: Phase 2 patients.

Groups in this outcome

Treatment (Lenalidomide, Melphalan, Prednisone)

Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide, Melphalan, Prednisone)26

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide, Melphalan, Prednisone)58Not reported4280Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        42
        upper Limit
        80
        value
        58
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    units
    Participants
description
OS was defined as the time from registration to death due to any cause. Patients who were alive were censored at date of last follow-up. The overall survival at 3 years (a percentage) is reported below.
dispersion Type
95% Confidence Interval
groups
  1. description
    Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression
    id
    OG000
    title
    Treatment (Lenalidomide, Melphalan, Prednisone)
param Type
NUMBER
population Description
Phase 2 patients.
reporting Status
POSTED
time Frame
registration to death (up to 3 years)
title
Overall Survival (OS) at 3 Years
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice